NICE announced Radium 223 would be allowed for patients with advanced prostate cancer. Tackle Trustee Hugh Gunn commented: “Tackle welcomes the decision by NICE to allow the use of Radium 223 in patients with advanced prostate cancer who have had treatment with docetaxel. We would however, like this treatment to be extended to the very small subgroup of patients who, for clinical reasons can’t be given docitaxel. These parents will then be denied this successful treatment, in an area where there are few options left.”